These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33023949)

  • 1. A Global and Integrated Analysis of CINSARC-Associated Genetic Defects.
    Lesluyes T; Chibon F
    Cancer Res; 2020 Dec; 80(23):5282-5290. PubMed ID: 33023949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CINSARC signature as a prognostic marker for clinical outcome in sarcomas and beyond.
    Chibon F; Lesluyes T; Valentin T; Le Guellec S
    Genes Chromosomes Cancer; 2019 Feb; 58(2):124-129. PubMed ID: 30387235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas.
    Le Guellec S; Lesluyes T; Sarot E; Valle C; Filleron T; Rochaix P; Valentin T; Pérot G; Coindre JM; Chibon F
    Ann Oncol; 2018 Aug; 29(8):1828-1835. PubMed ID: 29860427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas.
    Lagarde P; Przybyl J; Brulard C; Pérot G; Pierron G; Delattre O; Sciot R; Wozniak A; Schöffski P; Terrier P; Neuville A; Coindre JM; Italiano A; Orbach D; Debiec-Rychter M; Chibon F
    J Clin Oncol; 2013 Feb; 31(5):608-15. PubMed ID: 23319690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA sequencing validation of the Complexity INdex in SARComas prognostic signature.
    Lesluyes T; Pérot G; Largeau MR; Brulard C; Lagarde P; Dapremont V; Lucchesi C; Neuville A; Terrier P; Vince-Ranchère D; Mendez-Lago M; Gut M; Gut I; Coindre JM; Chibon F
    Eur J Cancer; 2016 Apr; 57():104-11. PubMed ID: 26916546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of prognostic markers in sarcomas base on a multi-omics analysis.
    Song Y; Yang K; Sun T; Tang R
    BMC Med Genomics; 2021 Jan; 14(1):31. PubMed ID: 33509178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of preoperative treatment on the CINSARC prognostic signature: translational research results from a phase 1 trial of the German Interdisciplinary Sarcoma Group (GISG 03).
    Jakob J; Lesluyes T; Simeonova-Chergou A; Wenz F; Hohenberger P; Chibon F; Le Guellec S
    Strahlenther Onkol; 2020 Mar; 196(3):280-285. PubMed ID: 31732782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature.
    Bertucci F; Niziers V; de Nonneville A; Finetti P; Mescam L; Mir O; Italiano A; Le Cesne A; Blay JY; Ceccarelli M; Bedognetti D; Birnbaum D; Mamessier E
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms.
    Lesluyes T; Delespaul L; Coindre JM; Chibon F
    Sci Rep; 2017 Jul; 7(1):5480. PubMed ID: 28710396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
    Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
    BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity.
    Chibon F; Lagarde P; Salas S; Pérot G; Brouste V; Tirode F; Lucchesi C; de Reynies A; Kauffmann A; Bui B; Terrier P; Bonvalot S; Le Cesne A; Vince-Ranchère D; Blay JY; Collin F; Guillou L; Leroux A; Coindre JM; Aurias A
    Nat Med; 2010 Jul; 16(7):781-7. PubMed ID: 20581836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complexity index in sarcoma and genomic grade index gene signatures in rhabdomyosarcoma of pediatric and adult ages.
    Ferrari A; Iannó MF; Carenzo A; Fortunato O; Casanova M; Chiaravalli S; Bergamaschi L; Bertulli R; Cattaneo F; Collini P; Trama A; Sozzi G; Massimino M; De Cecco L; Gasparini P
    Pediatr Blood Cancer; 2021 Jul; 68(7):e28987. PubMed ID: 33751795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma.
    Bertucci F; De Nonneville A; Finetti P; Perrot D; Nilbert M; Italiano A; Le Cesne A; Skubitz KM; Blay JY; Birnbaum D
    Ann Oncol; 2018 Feb; 29(2):459-465. PubMed ID: 29069276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study.
    Frezza AM; Stacchiotti S; Chibon F; Coindre JM; Italiano A; Romagnosa C; Bagué S; Dei Tos AP; Braglia L; Palmerini E; Quagliuolo V; Broto JM; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Beveridge RD; Lugowska I; Lesluyes T; Maestro R; Merlo FD; Casali PG; Gronchi A
    Cancer Med; 2023 Jan; 12(2):1350-1357. PubMed ID: 35848358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.
    Bertucci F; Finetti P; Monneur A; Perrot D; Chevreau C; Le Cesne A; Blay JY; Mir O; Birnbaum D
    Mol Oncol; 2019 Jul; 13(7):1577-1588. PubMed ID: 31131495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers.
    Fujiwara T; Kunisada T; Takeda K; Uotani K; Yoshida A; Ochiya T; Ozaki T
    Biomed Res Int; 2014; 2014():592868. PubMed ID: 25165708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas.
    Wong P; Hui A; Su J; Yue S; Haibe-Kains B; Gokgoz N; Xu W; Bruce J; Williams J; Catton C; Wunder JS; Andrulis IL; Gladdy R; Dickson B; O'Sullivan B; Liu FF
    Oncotarget; 2015 Nov; 6(36):39127-39. PubMed ID: 25970788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome wide methylation profiling of selected matched soft tissue sarcomas identifies methylation changes in metastatic and recurrent disease.
    Vargas AC; Gray LA; White CL; Maclean FM; Grimison P; Ardakani NM; Bonar F; Algar EM; Cheah AL; Russell P; Mahar A; Gill AJ
    Sci Rep; 2021 Jan; 11(1):667. PubMed ID: 33436720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer.
    Goncalves A; Finetti P; Birnbaum D; Bertucci F
    NPJ Breast Cancer; 2021 May; 7(1):48. PubMed ID: 33953185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity in sarcoma cell lines reveals enhanced motility of tetraploid versus diploid cells.
    Jemaà M; Abdallah S; Lledo G; Perrot G; Lesluyes T; Teyssier C; Roux P; van Dijk J; Chibon F; Abrieu A; Morin N
    Oncotarget; 2017 Mar; 8(10):16669-16689. PubMed ID: 28035071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.